Bispecific T-cell engager targeting DLL3 & CD3

"Tarlatamab, administered as a 10-mg dose every 2 weeks, showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. No new safety signals were identified"
#Immunology #Immunotherapy #LungCancer

https://www.nejm.org/doi/full/10.1056/NEJMoa2307980?query=featured_home